标题
Pharmacodynamics of current and emerging treatments for cervical cancer
作者
关键词
-
出版物
Expert Opinion on Drug Metabolism & Toxicology
Volume 15, Issue 8, Pages 671-682
出版商
Informa UK Limited
发表日期
2019-07-25
DOI
10.1080/17425255.2019.1648431
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs
- (2019) Sheba Plamthottam et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
- (2018) Chengying Xie et al. CANCER SCIENCE
- Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
- (2018) Lindsey E. Minion et al. GYNECOLOGIC ONCOLOGY
- A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
- (2018) Partha Basu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
- (2018) Randi B. Gombos et al. PLoS One
- The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
- (2018) Yang-chun Feng et al. Cancer Management and Research
- Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
- (2018) Bobby Daly et al. JAMA Oncology
- Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer
- (2018) Yoichi Aoki et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.
- (2018) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- RNA-based therapies have their day
- (2018) EBioMedicine
- A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers
- (2018) Sanja Stevanovic et al. CLINICAL CANCER RESEARCH
- Cemiplimab: First Global Approval
- (2018) Anthony Markham et al. DRUGS
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
- (2018) Pedro T. Ramirez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- (2017) Jean-Sebastien Frenel et al. JOURNAL OF CLINICAL ONCOLOGY
- Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
- (2017) Wen Yang et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
- (2017) Chaoqi Liu et al. Molecular Medicine Reports
- Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4
- (2017) Samarchith P Kurup et al. NATURE MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Product review on the Anti-PD-L1 antibody atezolizumab
- (2017) Neil J. Shah et al. Human Vaccines & Immunotherapeutics
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators
- (2017) Yong Qin et al. Frontiers in Immunology
- Global strategies for the treatment of early-stage and advanced cervical cancer
- (2016) Alfonso Dueñas-González et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Daratumumab: First Global Approval
- (2016) Kate McKeage DRUGS
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Phase 1 Trial of Bone Marrow Sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Gemcitabine in Stage IB-IVA Cervical Cancer
- (2016) L.K. Mell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
- (2016) A Marijne Heeren et al. MODERN PATHOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
- (2016) James M. Wilson et al. RADIOTHERAPY AND ONCOLOGY
- Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
- (2016) Marij J. Welters et al. Science Translational Medicine
- Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
- (2016) Eric Deutsch et al. Oncotarget
- Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors
- (2016) Krijn K. Dijkstra et al. JAMA Oncology
- Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway
- (2015) Tong Xiang et al. CANCER LETTERS
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
- (2015) Louisa Mezache et al. MODERN PATHOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis
- (2014) Fausto Petrelli et al. GYNECOLOGIC ONCOLOGY
- Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study
- (2014) Paul A. DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of RNAi technology for targeted therapy — A track of siRNA based agents to RNAi therapeutics
- (2014) Yinjian Zhou et al. JOURNAL OF CONTROLLED RELEASE
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer
- (2014) SHAN LIAO et al. ONCOLOGY REPORTS
- Angiogenesis and antiangiogenic agents in cervical cancer
- (2014) Silverio Tomao et al. OncoTargets and Therapy
- Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
- (2014) Tae Jin Kim et al. Nature Communications
- A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
- (2013) Mayu Yunokawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention
- (2013) Soren Gantt et al. CURRENT OPINION IN ONCOLOGY
- Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers
- (2013) Charles A. Kunos et al. GYNECOLOGIC ONCOLOGY
- Evolution in Fertility-Preserving Options for Early-Stage Cervical Cancer
- (2013) Marie Plante INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- New Insights into the Mechanism Underlying the Synergistic Action of Ionizing Radiation With Platinum Chemotherapeutic Drugs: The Role of Low-Energy Electrons
- (2013) Mohammad Rezaee et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- RTOG 0417: Efficacy of Bevacizumab in Combination With Definitive Radiation Therapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma
- (2013) Tracey Schefter et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Landscape of genomic alterations in cervical carcinomas
- (2013) Akinyemi I. Ojesina et al. NATURE
- Lm-LLO-Based Immunotherapies and HPV-Associated Disease
- (2012) Anu Wallecha et al. Journal of Oncology
- Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
- (2011) N. Katsumata et al. ANNALS OF ONCOLOGY
- Conservative management of early stage cervical cancer: Is there a role for less radical surgery?
- (2011) Kathleen M. Schmeler et al. GYNECOLOGIC ONCOLOGY
- Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
- (2011) Alfonso Dueñas-González et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
- (2010) C. A. Kunos et al. CLINICAL CANCER RESEARCH
- Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers
- (2010) Charles A. Kunos et al. RADIATION RESEARCH
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs
- (2009) L. Bousarghin et al. MOLECULAR CANCER THERAPEUTICS
- Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer
- (2008) Andrea Maneo et al. GYNECOLOGIC ONCOLOGY
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now